Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30458
Formulation and Evaluation of Niosomes Containing an Antihypertensive Drug

Authors: Sunil Kamboj, Suman Bala, Vipin Saini

Abstract:

Niosomes were formulated with an aim of enhancing the oral bioavailability of losartan potassium and formulated in different molar ratios of surfactant, cholesterol and dicetyl phosphate. The formulated niosomes were found in range of 54.98 µm to 107.85 µm in size. Formulations with 1:1 ratio of surfactant and cholesterol have shown maximum entrapment efficiencies. Niosomes with sorbitan monostearate showed maximum drug release and zero order release kinetics, at the end of 24 hours. The in vivo study has shown the significant enhancement in oral bioavailability of losartan potassium in rats, after a dose of 10 mg/kg. The average relative bioavailability in relation with pure drug solution was found 2.56, indicates more than two fold increase in oral bioavailability. A significant increment in MRT reflects the release retarding ability of the vesicles. In conclusion, niosomes could be a promising delivery of losartan potassium with improved oral bioavailability and prolonged release profiles.

Keywords: controlled release, non-ionic surfactant vesicles, losartan potassium, oral bioavailability

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1123548

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1402

References:


[1] Abdel M. M., Zaki N. M., Mansour S., Geneidi A. S., 2014. Bioavailability Enhancement of Verapamil HCl via Intranasal Chitosan Microspheres. Eur. J. Pharm. Sci. 51, 59-66.
[2] Bandyopadhyay P., Johnson M., 2007. Fatty Alcohols or Fatty Acids as Niosomal Hybrid Carrier: Effect on Vesicle Size, Encapsulation Efficiency and in vitro Dye Release. Colloids. Surf. B. Biointerfaces. 58 (1), 68-71.
[3] Bansal S., Aggarwal G., Chandel P., Harikumar S. L., 2013. Design and Development of Cefdinir Niosomes for Oral Delivery. J. Pharm. Bioallied. Sci. 5 (4), 318-325.
[4] Bayindir Z.S., Yuksel N., 2010. Characterization of Niosomes Prepared with Various Nonionic Surfactants for Paclitaxel Oral Delivery. J. Pharm. Sci. 99 (4), 2049-2060.
[5] Chen D., Xia D., Li X., Zhu Q., Yu H., Zhu C., Gan Y., 2013. Comparative Study of Pluranic (®) F127-Modified Liposomes and Chitosan-Modified Liposomes for Mucus Penetration and Oral Absorption of Cyclosporine A in rats. Int. J. Pharm. 449 (1-2), 1-9.
[6] Chou T. H., Liang C. H., Lee Y. C., Yeh L. H., 2013. Effect of Lipid Composition on Physicochemical Characteristics and Cytotoxicity of Vesicles Composed of Cationic and Anionic Dialkyl Lipids. Phys. Chem. Chem. Phys. 16 (4), 1545-1553.
[7] Dash S., Murthy P. N., Nath L., Chowdhury P., 2010. Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems. Acta. Pol. Pharm. Drug. Res. 67 (3), 217-223.
[8] Haeri A., Sadeghian S., Rabbani S., Anvari M. S., Lavasanifar A., Amini M., Dadashzadeh S. 2013. Sirolimus-Loaded Stealth Colloidal Systems Attenuate Neointimal Hyperplasia after Balloon Injury: A Comparision of Phospholipid Micelles and Liposomes. Int. J. Pharm. 455 (1-2), 320-330.
[9] Hasan A. A., 2014. Design and in vitro Characterization of Small Unilamellar Niosomes as Ophthalmic Carrier of Dorzolamide Hydrochloride. Pharm. Dev. Technol. 19 (6), 748-754.
[10] Ibuki C., Seino Y., Otsuka T., Mizuno K., 2014. The Fixed-Dose Combination of Losartan/Hydrochlorothiazide Elicits Potent Blood Pressure Lowering during Nighttime in Obese Hypertensive Patients. J. Clin. Med. Res. 6 (1), 8-16.
[11] Jadon P. S., Gajbhiye V., Jadon R. S., Gajbhiye K. R., Ganesh N., 2009. Enhanced Oral Bioavailability of Griseofulvin via Niosomes. AAPS PharmSciTech. 10 (4), 1186-1192.
[12] Jin Y., Wen J., Garg S., Liu D., Zhou Y., Teng L., Zhang W., 2013. Development of a Novel Niosomal System for Oral Delivery of Gingko biloba Extract. Int. J. Nanomedicine.8, 421-430.
[13] Kamboj S., Saini V., Bala S., 2014. Formulations and Characterization of Drug Loaded Non-Ionic Surfactant Vesicles (Niosomes) for Oral Bioavailability Enhancement. Sci. World. J. 2014, 1-9.
[14] Kamboj S., Saini V., Maggon N., Bala S., Jhawat V., 2013. Vesicular Drug Delivery Systems: A Novel Approach for Drug Targeting. Int. J. Drug. Deliv. 5 (2), 121-130.
[15] Lee S. C., Lee K. E., Kim J. J., Lim S. H., 2005. The Effect of Cholesterol in the Liposome Bilayer on the Stabilization of Incorporated Retinol. J. Liposome. Res., 15 (3-4), 157-166.